Sagimet Biosciences Shares Rise on Licensing Agreement With Teva

Dow Jones12-18 00:23

By Katherine Hamilton

Sagimet Biosciences shares rose after the company said it had entered into a global licensing agreement.

The stock rose 13% to $6.83 on Wednesday. Shares are up 48% this year.

The San Mateo, Calif., biopharmaceutical company said Wednesday it signed an agreement with Assia Chemical Industries, doing business as TAPI, which is a subsidiary of Teva Pharmaceutical Industries.

Under the agreement, Sagimet will have a global exclusive license to certain intellectual property rights covering forms of the active pharmaceutical ingredient in TAPI's drug resmetirom.

The rights will be used for Sagimet's technical evaluation and manufacture, as well as potential further development of a fixed-dose combination product containing denifanstat and resmetirom.

Sagimet is developing trials to see if the combined drugs can effectively treat adults with metabolic dysfunction-associated steatohepatitis (MASH).

The company plans to move the trial into phase 2 in the second half of 2026.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 17, 2025 11:23 ET (16:23 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592826914?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 00:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592826914","market":"nz","top_or_hot":-1,"title":"Sagimet Biosciences Shares Rise on Licensing Agreement With Teva","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences</a> shares rose after the company said it had entered into a global licensing agreement. \n</p>\n<p>\n  The stock rose 13% to $6.83 on Wednesday. Shares are up 48% this year. \n</p>\n<p>\n  The San Mateo, Calif., biopharmaceutical company said Wednesday it signed an agreement with Assia Chemical Industries, doing business as TAPI, which is a subsidiary of <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical Industries. \n</p>\n<p>\n  Under the agreement, Sagimet will have a global exclusive license to certain intellectual property rights covering forms of the active pharmaceutical ingredient in TAPI's drug resmetirom. \n</p>\n<p>\n  The rights will be used for Sagimet's technical evaluation and manufacture, as well as potential further development of a fixed-dose combination product containing denifanstat and resmetirom. \n</p>\n<p>\n  Sagimet is developing trials to see if the combined drugs can effectively treat adults with metabolic dysfunction-associated steatohepatitis (MASH). \n</p>\n<p>\n  The company plans to move the trial into phase 2 in the second half of 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2025 11:23 ET (16:23 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sagimet Biosciences Shares Rise on Licensing Agreement With Teva</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSagimet Biosciences Shares Rise on Licensing Agreement With Teva\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-18 00:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences</a> shares rose after the company said it had entered into a global licensing agreement. \n</p>\n<p>\n  The stock rose 13% to $6.83 on Wednesday. Shares are up 48% this year. \n</p>\n<p>\n  The San Mateo, Calif., biopharmaceutical company said Wednesday it signed an agreement with Assia Chemical Industries, doing business as TAPI, which is a subsidiary of <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical Industries. \n</p>\n<p>\n  Under the agreement, Sagimet will have a global exclusive license to certain intellectual property rights covering forms of the active pharmaceutical ingredient in TAPI's drug resmetirom. \n</p>\n<p>\n  The rights will be used for Sagimet's technical evaluation and manufacture, as well as potential further development of a fixed-dose combination product containing denifanstat and resmetirom. \n</p>\n<p>\n  Sagimet is developing trials to see if the combined drugs can effectively treat adults with metabolic dysfunction-associated steatohepatitis (MASH). \n</p>\n<p>\n  The company plans to move the trial into phase 2 in the second half of 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2025 11:23 ET (16:23 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4559","symbol_name":"巴菲特持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2592826914","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592826914","pubTimestamp":1765988580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sagimet Biosciences shares rose after the company said it had entered into a global licensing agreement.The stock rose 13% to $6.83 on Wednesday. Shares are up 48% this year.The San Mateo, Calif., biopharmaceutical company said Wednesday it signed an agreement with Assia Chemical Industries, doing business as TAPI, which is a subsidiary of Teva Pharmaceutical Industries.Under the agreement, Sagimet will have a global exclusive license to certain intellectual property rights covering forms of the active pharmaceutical ingredient in TAPI's drug resmetirom.The rights will be used for Sagimet's technical evaluation and manufacture, as well as potential further development of a fixed-dose combination product containing denifanstat and resmetirom.Sagimet is developing trials to see if the combined drugs can effectively treat adults with metabolic dysfunction-associated steatohepatitis .The company plans to move the trial into phase 2 in the second half of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4559":"巴菲特持仓","BK4596":"哈里斯概念","BK4007":"制药","BK4584":"避孕概念","BK4566":"资本集团","TEVA":"梯瓦制药","SGMT":"Sagimet Biosciences Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4557":"大麻股","BK4139":"生物科技","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC"},"translate_title":"Sagimet Biosciences股价因与梯瓦(Teva)达成许可协议而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGMT":1.5,"TEVA":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\nSagimet Biosciences shares rose after the company said it had entered into a global licensing agreement. \n\n\n  The stock rose 13% to $6.83 on Wednesday. Shares are up 48% this year. \n\n\n  The San Mateo, Calif., biopharmaceutical company said Wednesday it signed an agreement with Assia Chemical Industries, doing business as TAPI, which is a subsidiary of Teva Pharmaceutical Industries. \n\n\n  Under the agreement, Sagimet will have a global exclusive license to certain intellectual property rights covering forms of the active pharmaceutical ingredient in TAPI's drug resmetirom. \n\n\n  The rights will be used for Sagimet's technical evaluation and manufacture, as well as potential further development of a fixed-dose combination product containing denifanstat and resmetirom. \n\n\n  Sagimet is developing trials to see if the combined drugs can effectively treat adults with metabolic dysfunction-associated steatohepatitis (MASH). \n\n\n  The company plans to move the trial into phase 2 in the second half of 2026. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 11:23 ET (16:23 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592826914","isCrawlerRequest":true}